Aquestive Therapeutics Inc (AQST)vsHaleon plc (HLN)
AQST
Aquestive Therapeutics Inc
$4.25
0.00%
HEALTHCARE · Cap: $469.25M
HLN
Haleon plc
$9.70
-1.02%
HEALTHCARE · Cap: $44.17B
Smart Verdict
WallStSmart Research — data-driven comparison
Haleon plc generates 22084% more annual revenue ($11.15B vs $50.27M). HLN leads profitability with a 14.5% profit margin vs -137.1%. HLN earns a higher WallStSmart Score of 48/100 (D+).
AQST
Avoid28
out of 100
Grade: F
HLN
Hold48
out of 100
Grade: D+
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-49.2%
Fair Value
$2.56
Current Price
$4.25
$1.69 premium
Intrinsic value data unavailable for HLN.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Revenue surging 65.7% year-over-year
Conservative balance sheet, low leverage
Reasonable price relative to book value
Strong operational efficiency at 23.9%
Areas to Watch
0.0% earnings growth
Smaller company, higher risk/reward
ROE of 0.0% — below average capital efficiency
Weak financial health signals
Expensive relative to growth rate
2.2% revenue growth
Grey zone — moderate risk
Earnings declined 4.5%
Comparative Analysis Report
WallStSmart ResearchBull Case : AQST
The strongest argument for AQST centers on Revenue Growth, Debt/Equity. Revenue growth of 65.7% demonstrates continued momentum.
Bull Case : HLN
The strongest argument for HLN centers on Price/Book, Operating Margin.
Bear Case : AQST
The primary concerns for AQST are EPS Growth, Market Cap, Return on Equity.
Bear Case : HLN
The primary concerns for HLN are PEG Ratio, Revenue Growth, Altman Z-Score.
Key Dynamics to Monitor
AQST profiles as a hypergrowth stock while HLN is a value play — different risk/reward profiles.
AQST carries more volatility with a beta of 1.43 — expect wider price swings.
AQST is growing revenue faster at 65.7% — sustainability is the question.
HLN generates stronger free cash flow (792M), providing more financial flexibility.
Bottom Line
HLN scores higher overall (48/100 vs 28/100). Both earn "Hold" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Aquestive Therapeutics Inc
HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC · USA
Aquestive Therapeutics, Inc., a pharmaceutical company, focuses on identifying, developing, and marketing various products to address unmet medical needs in the United States and internationally. The company is headquartered in Warren, New Jersey.
Haleon plc
HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC · USA
Haleon plc (HLN) is a leading global consumer health company, emerging as a spin-off from GlaxoSmithKline, dedicated to providing innovative health solutions through a robust portfolio of trusted brands, including Sensodyne, Panadol, and Voltaren. Focused on key segments such as oral care, pain relief, and dietary supplements, Haleon addresses evolving consumer needs while leveraging strong brand equity for sustained market presence. The company's commitment to sustainability and ongoing innovation, alongside strategic investments in product development, positions Haleon favorably for long-term growth and enhanced health outcomes, ultimately maximizing value for shareholders.
Visit Website →Compare with Other DRUG MANUFACTURERS - SPECIALTY & GENERIC Stocks
Want to dig deeper into these stocks?